Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Bim de Klein"'
Autor:
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Frank Rolfs, Catrin Lutz, Jessica K. Lee, Sjoerd Klarenbeek, Ian M. Silverman, Stefano Annunziato, Chang S. Chan, Sander R. Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R. de Goeij-de Haas, Gregory M. Riedlinger, Hua Ke, Russell Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H. van Miltenburg, Natalie Proost, Huiling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R. de Ruiter, Ute Boon, Renske de Korte-Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K. Abou-Alfa, Jeffrey S. Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M. Ali, Timothy C. Burn, Connie R. Jimenez, Shridar Ganesan, Lodewyk F. A. Wessels, Jos Jonkers
Publikováno v:
Zingg, Daniel; Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M; Rolfs, Frank; Lutz, Catrin; Lee, Jessica K; Klarenbeek, Sjoerd; Silverman, Ian M; Annunziato, Stefano; Chan, Chang S; Piersma, Sander R; Eijkman, Timo; Badoux, Madelon; Gogola, Ewa; Siteur, Bjørn; Sprengers, Justin; de Klein, Bim; de Goeij-de Haas, Richard R; Riedlinger, Gregory M; ... (2022). Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature, 609(7929), E13. Springer Nature 10.1038/s41586-022-05287-8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42007ac1db1800b2f49158a1d120fdb2
Autor:
Catrin Lutz, Madelon Badoux, Timo Eijkman, Bim de Klein, Ji-Ying Song, Linda Henneman, Colinda Scheele, Jelle Wesseling, Jos Jonkers
Publikováno v:
Cancer Prevention Research. 15:PR003-PR003
DCIS has been virtually unknown before the introduction of breast cancer screening programs in the 1980s. Since then, its incidence has been rising steeply and it now accounts for about 25% of all newly diagnosed ‘breast cancer’ cases. Despite th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::264764bed8651c96c7690370ee78ebfb
https://doi.org/10.1158/1940-6215.dcis22-pr003
https://doi.org/10.1158/1940-6215.dcis22-pr003
Autor:
Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Frank Rolfs, Catrin Lutz, Jessica K. Lee, Sjoerd Klarenbeek, Ian M. Silverman, Stefano Annunziato, Chang S. Chan, Sander R. Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R. de Goeij-de Haas, Gregory M. Riedlinger, Hua Ke, Russell Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H. van Miltenburg, Natalie Proost, Huiling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R. de Ruiter, Ute Boon, Renske de Korte-Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K. Abou-Alfa, Jeffrey S. Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M. Ali, Timothy C. Burn, Connie R. Jimenez, Shridar Ganesan, Lodewyk F. A. Wessels, Jos Jonkers
Publikováno v:
Zingg, Daniel; Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M; Rolfs, Frank; Lutz, Catrin; Lee, Jessica K; Klarenbeek, Sjoerd; Silverman, Ian M; Annunziato, Stefano; Chan, Chang S; Piersma, Sander R; Eijkman, Timo; Badoux, Madelon; Gogola, Ewa; Siteur, Bjørn; Sprengers, Justin; de Klein, Bim; de Goeij-de Haas, Richard R; Riedlinger, Gregory M; ... (2022). Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature, 608(7923), pp. 609-617. Springer Nature 10.1038/s41586-022-05066-5
Zingg, D, Bhin, J, Yemelyanenko, J, Kas, S M, Rolfs, F, Lutz, C, Lee, J K, Klarenbeek, S, Silverman, I M, Annunziato, S, Chan, C S, Piersma, S R, Eijkman, T, Badoux, M, Gogola, E, Siteur, B, Sprengers, J, de Klein, B, de Goeij-de Haas, R R, Riedlinger, G M, Ke, H, Madison, R, Drenth, A P, van der Burg, E, Schut, E, Henneman, L, van Miltenburg, M H, Proost, N, Zhen, H, Wientjens, E, de Bruijn, R, de Ruiter, J R, Boon, U, de Korte-Grimmerink, R, van Gerwen, B, Féliz, L, Abou-Alfa, G K, Ross, J S, van de Ven, M, Rottenberg, S, Cuppen, E, Chessex, A V, Ali, S M, Burn, T C, Jimenez, C R, Ganesan, S, Wessels, L F A & Jonkers, J 2022, ' Truncated FGFR2 is a clinically actionable oncogene in multiple cancers ', Nature, vol. 608, no. 7923, pp. 609-617 . https://doi.org/10.1038/s41586-022-05066-5
Nature, 608(7923), 609-617. Nature Publishing Group
Zingg, D, Bhin, J, Yemelyanenko, J, Kas, S M, Rolfs, F, Lutz, C, Lee, J K, Klarenbeek, S, Silverman, I M, Annunziato, S, Chan, C S, Piersma, S R, Eijkman, T, Badoux, M, Gogola, E, Siteur, B, Sprengers, J, de Klein, B, de Goeij-de Haas, R R, Riedlinger, G M, Ke, H, Madison, R, Drenth, A P, van der Burg, E, Schut, E, Henneman, L, van Miltenburg, M H, Proost, N, Zhen, H, Wientjens, E, de Bruijn, R, de Ruiter, J R, Boon, U, de Korte-Grimmerink, R, van Gerwen, B, Féliz, L, Abou-Alfa, G K, Ross, J S, van de Ven, M, Rottenberg, S, Cuppen, E, Chessex, A V, Ali, S M, Burn, T C, Jimenez, C R, Ganesan, S, Wessels, L F A & Jonkers, J 2022, ' Truncated FGFR2 is a clinically actionable oncogene in multiple cancers ', Nature, vol. 608, no. 7923, pp. 609-617 . https://doi.org/10.1038/s41586-022-05066-5
Nature, 608(7923), 609-617. Nature Publishing Group
Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer1. However, clinical responses to FGFR inhibitors have remained variable1–9, emp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f8325919e6300d2961522f5a44b67f
https://pubmed.ncbi.nlm.nih.gov/36050473
https://pubmed.ncbi.nlm.nih.gov/36050473